SCHEMBL4980300

SCHEMBL4980300

O=C(Cl)C=C1c2ccccc2C(=O)c2ccccc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
CDC25B P30305 1/20 0.50
KMT2A Q03164 1/20 0.50
BCL2 P10415 1/20 0.43
MCL1 Q07820 1/20 0.43
TUBB4A P04350 1/20 0.43
TUBB P07437 1/20 0.43
TUBA3C P0DPH7 1/20 0.43
AR P10275 1/20 0.43
TUBA1B P68363 1/20 0.43
TUBA4A P68366 1/20 0.43
TUBB4B P68371 1/20 0.43
TUBB3 Q13509 1/20 0.43
TUBB2A Q13885 1/20 0.43
TUBB8 Q3ZCM7 1/20 0.43
TUBA3E Q6PEY2 1/20 0.43
TUBA1A Q71U36 1/20 0.43
TUBA1C Q9BQE3 1/20 0.43
TUBB6 Q9BUF5 1/20 0.43
TUBB2B Q9BVA1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4981378 0.81 MEN1 (0.52) MEN1CDC25BKMT2A
Anthraquinone SCHEMBL7092793 0.79 MEN1 (0.71) MEN1CDC25BKMT2ABCL2MCL1
Anthraquinone SCHEMBL11041458 0.77 MEN1 (0.67) MEN1CDC25BKMT2ABCL2MCL1
SCHEMBL4726272 0.76 NFE2L2 (0.48)
SCHEMBL4981734 0.75 CDC25A (0.47) MEN1CDC25BKMT2AAR
SCHEMBL4981758 0.74 TGM2 (0.49)
Anthraquinone SCHEMBL28942426 0.74 MEN1 (0.92) MEN1CDC25BKMT2ABCL2MCL1
Anthraquinone SCHEMBL1297723 0.72 MEN1 (0.67) MEN1CDC25BKMT2ABCL2MCL1
SCHEMBL4981501 0.72 MMP9 (0.47) MEN1KMT2ATUBB4ATUBBTUBA3C
Anthraquinone SCHEMBL9879416 0.71 KMT2A (0.57) MEN1CDC25BKMT2ABCL2MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051463-A1 ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS AETERNA ZENTARIS GMBH (DE) 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051463-A1 ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS TUBB1, TUBA1C, TUBB3 MEN1 603/4885CDC25B 404/4885KMT2A 4144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.